Karbicombi (Hydrochlorothiazide, Candesartan Cilexetil)

Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted tubule of the kidney, promoting diuresis. The resulting loss of fluid reduces plasma volume, which contributes to a decrease in blood pressure when used together with the ARB component.

The specific dose of Karbicombi is determined by the prescribing clinician based on the patient’s blood‑pressure readings, renal function, and overall health status. Dosage adjustments are made individually; patients should follow the prescriber’s instructions and not alter the dose on their own.

Safety of Karbicombi in pregnancy or while breastfeeding has not been fully established. Women who are pregnant, planning pregnancy, or nursing should discuss potential risks and benefits with their healthcare provider before starting or continuing therapy.

To order Karbicombi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Karbicombi offers a dual mechanism by pairing a thiazide diuretic with an ARB, which can provide more consistent blood‑pressure control than monotherapy with either class alone. Compared with ACE inhibitors, ARBs have a lower incidence of cough, and the thiazide component adds diuretic benefit without the metabolic effects of some other diuretics.

Karbicombi tablets should be stored at room temperature, below 25 °C. Keep them in the original packaging, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Karbicombi is taken orally, usually once daily, with or without food, as directed by a healthcare professional. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe dehydration, electrolyte imbalances such as hyperkalemia, acute kidney injury, angioedema, and marked hypotension. Patients should be educated to recognize symptoms like swelling of the face or throat, sudden dizziness, or drastic drops in blood pressure and seek medical attention promptly.

Karbicombi is contraindicated in patients with known hypersensitivity to either component, severe renal impairment, severe hepatic disease, or in those taking other potassium‑sparing agents that could cause dangerous hyperkalemia. It should also be used with caution in individuals with a history of gout or electrolyte disorders.